Caroline Bradford

NCHR Agrees with CDC Draft Recommendation to Remove Liraglutide and Pertuzumab from the National Institute for Occupational Safety and Health Hazardous Drugs in Healthcare Settings List

February 15th, 2024: NCHR supports the CDC recommendation to remove Liraglutide and Pertuzumab drugs from the NIOSH List of Hazardous Drugs in Healthcare Settings. We agree that due to the to the drugs’ low bioavailability and limited risk of occupational exposures these drugs are unlikely to pose a harm to healthcare workers.

Comments of National Center for Health Research on USPSTF Draft Research Plan for BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing

February 14, 2024: NCHR supports USPSTF BRCA-Related Cancer research plan but recommends evaluating the impact of how risk information is explained in genetic counseling & treatment options. Our primary concern is providing short-term and long-term risk information and absolute risk and benefit statistics as well as relative risks and benefits.

NCHR Comment- Menu Labeling: Supplemental Guidance for Industry (Edition 2)

The FDA recommends that chain restaurants publish information on calories and added sugars on standard menus and also on third-party platforms such as Grubhub and Ubereats. NCHR agrees with FDA’s plan to improve info available to consumers but urges the agency to make these recommendations mandatory to ensure the compliance needed to provide useful health information to consumers.

A Closer Look at Aduhelm, CTE, and the Super Bowl: Insights from STAT Readers

February 11, 2024: NCHR was quoted in Medriva regarding our commentary on the evidence FDA should require to prove safety and efficacy of treatments used by older patients, which was also discussed in Letters to the Editor and comments to STAT.

Medicare has different standards than the FDA. That’s how it should be

STAT News, February 2, 2024: NCHR’s Diana Zuckerman’s commentary in STAT News explains why Medicare should not pay for every medical product that FDA approves, since some are more likely to harm rather than help Medicare patients. She points out that FDA does not require diversity in clinical trials and rarely includes enough older and less healthy patients that tend to rely on Medicare.